Eli Lilly won European Medicines Agency human medicines committee (CHMP) endorsement for its oral GLP-1 pill orforglipron, positioning the drug to challenge Novo Nordisk’s oral Wegovy franchise. The committee’s positive opinion gives Lilly a regulatory pathway in Europe and accelerates competitive pressure in the oral obesity market. The move highlights the shift from injectable GLP-1 dominance toward oral options where dosing convenience can become a decisive adoption lever. Lilly’s next steps hinge on final EU approval and subsequent uptake dynamics versus established class leaders.